960067-33-8

Basic information

• Product Name: 2-(2-(Difluoromethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
• Synonyms: 2-(2-(Difluoromethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane;2-Difluoromethoxyphenylboronic acid, pinacol ester;3-hydroxy-2,3-dimethylbutan-2-yl hydrogen (2-(difluoromethoxy)phenyl)boronate;2-(Difluoromethoxy)benzeneboronicacid,pinacolester
• CAS NO: 960067-33-8
• Molecular Formula: C₁₃H₁₇BF₂O₃
• Molecular Weight: 270.0800864
• Mol File: 960067-33-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 326.5±37.0 °C(Predicted)
• Appearance: /
• Density: 1.13±0.1 g/cm3(Predicted)
• Storage Temp.: Refrigerated.
• CAS DataBase Reference: 2-(2-(Difluoromethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-(Difluoromethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(960067-33-8)
• EPA Substance Registry System: 2-(2-(Difluoromethoxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(960067-33-8)

Safety Data

• Hazardous Substances Data: 960067-33-8(Hazardous Substances Data)

Usage

Uses

2-Difluoromethoxyphenylboronic Acid, Pinacol Ester is an intermediate in preparation of pyridine derivatives as voltage-gated sodium channel modulators useful in the treatment of pain.

Upstream product

• 95-56-7 2-hydroxybromobenzene 
• 175278-33-8 1-bromo-2-(dilfluoromethoxy)benzene 
• 25015-63-8 4,4,5,5-tetramethyl-[1,3,2]-dioxaboralane 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1079400-22-8 N-{6-amino-5-[2-(difluoromethoxy)phenyl]pyridin-2-yl}-1-methyl-1H-pyrazole-5-carboxamide 

Relevant articles and documents

KRAS G12D INHIBITORS

The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

Balancing potency, metabolic stability and permeability in pyrrolopyrimidine-based EGFR inhibitors

The present study describes our continuous effort to develop epidermal growth factor receptor (EGFR) inhibitors based on the 6-aryl-pyrrolo[2,3-d]pyrimidin-4-amine scaffold. The activity-ADME space has been evaluated by synthesizing 43 new structures, including four variations of the 4-amino group and 34 different substitution patterns in the 6-aryl moiety. Most of the new pyrrolopyrimidines were highly active, with twelve analogues possessing lower IC50values than the commercial drug Erlotinib in enzymatic assays. Ten EGFR inhibitors were also profiled in cell studies using the Ba/F3-EGFRL858Rreporter cells, and all revealed nanomolar activity. However, some of the privileged structures in terms of potency had ADME short-comings: compounds containing amides, sulfonamides, amine and hydroxymethyl substituents in the 6-aryl group had low permeability and high efflux, derivatives having (R)-3-amino-3-phenylpropan-1-ol at C-4 induced hERG inhibition properties, and metabolic lability was seen for compounds having (S)-2-methoxy-1-phenylethan-1-amine at C-4. Based on a trade-off between enzymatic activity, cellular potency and ADME properties, (S)-2-phenyl-2-((6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)ethan-1-ol appeared as the most promising drug candidate. Cellular studies indicate this compound to have therapeutic use in EGFR driven diseases.